Previous 10 | Next 10 |
A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus. Firms are forging ahead with testing, treatment and vaccine research and product development. Results of even the most promising treatments, however, are not yet clear cut....
Foreword Any collection of stocks is more clearly understood when subjected to yield-based (dog catcher) analysis, these dividend-boosted batches are perfect for the Arnold dog catcher process. Here is your August 3 to 24 combined data from Barron's for 112 dividend-paying equities as supp...
Co-produced with PendragonY Why Invest in Healthcare and Biotech Closed-End Funds? Tekla Healthcare Investors ( HQH ) has been an HDO holding for more than four years, and in April we upgraded it to a "Must Own", in the midst of the COVID-19 outbreak. As a closed-end fund t...
There's one big question on every investor’s mind. Are we entering a new bull market, or is the recent market recovery simply a bear trap? Obviously, there's a serious concern about the second wave of coronavirus and resulting shutdowns, which may or may not come, but does cause a lot...
Author's note: This article was released to CEF/ETF Income Laboratory members on June 8, 2020. Please check latest data before investing. The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund [CEF] sectors in t...
By Wvan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group, and Wendy Lam, Ph.D., Portfolio Manager and Research Analyst, Franklin Biotechnology Discovery Fund Innovation has always been a key driver for the biotechnology industry. Even in the midst of the CO...
Author's note: This article was released to members on June 1, 2020. Please check latest data before investing. The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund [CEF] sectors in the last week, as well as...
On May 8, 2020, Tekla World Healthcare Fund declared its monthly cash distribution of $0.1167 per share. The record date for the monthly cash distribution is May 20, 2020 and the payable date is May 29, 2020. The Fund will trade ex-distribution on May 19, 2020. Note that only participants...
On May 8, 2020, Tekla Healthcare Opportunities Fund declared its monthly cash distribution of $0.1125 per share. The record date for the monthly cash distribution is May 20, 2020 and the payable date is May 29, 2020. The Fund will trade ex-distribution on May 19, 2020. Note that only part...
Closed-end-funds offer investors exposure to actively managed investment portfolios that oftentimes feature more dynamic strategies compared to passive ETFs. While many investors are attracted to the income profile of the various funds with corresponding impressively high yields and managed ...
News, Short Squeeze, Breakout and More Instantly...
TeklaLife Sciences Investors Company Name:
HQL Stock Symbol:
NYSE Market:
TeklaLife Sciences Investors Website:
2024-07-25 05:00:37 ET Few people pay much attention to the management team of a closed-end fund (CEF). But it’s becoming a much more critical factor driving CEF upside (and downside!), as well as these funds’ 8%+ dividend payouts. I was reminded of this recently by a ...
PHILADELPHIA, PA / ACCESSWIRE / June 26, 2024 / abrdn Life Sciences Investors ("HQL") announced today the results of the Annual Meeting of Shareholders (the "Meeting"), held on June 25, 2024. As of the record date, April 1, 2024, HQL had outstanding 27,350,517 shares of common stock. 87.84% o...
2024-04-22 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...